Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 37kWORD 9k
11 January 2022
P-000113/2022
Priority question for written answer  P-000113/2022
to the Commission
Rule 138
Asim Ademov (PPE)
 Subject: Early review of the biocidal product ‘Zineb’ under Article 15 of Regulation (EU) No 528/2012

We understand that Zineb has been authorised for use in the EU, under Regulation (EU) No 92/2014, up until 2025. However, the Commission has launched an early review of Zineb under Article 15 of Regulation (EU) No 528/2012.

1. Can the Commission indicate the reasons for this early review, and for the process followed and the state of play with this review?

2. Can the Commission also state whether the applicant for the initial approval of Zineb is involved in that process and whether it is being allowed to carry out and submit new research aimed at addressing the reasons for the early review?

Original language of question: BG
Last updated: 14 January 2022Legal notice - Privacy policy